Sysmex has received manufacturing and marketing approval for its in-vitro diagnostic test to detect amyloid beta (Aβ) accumulation in the brain, which is an indicator of Alzheimer’s disease.

The test, HISCL β-Amyloid 1-42 Assay Kit and the HISCL β-Amyloid 1-40 Assay Kit, uses a small amount of blood sample for measuring the Aβ levels using the company’s automated immunoassay system HISCL-5000/HISCL-800.

The company’s HISCL-Series uses chemiluminescence enzyme immunoassay (CLEIA) as its measurement principle.

The HISCL-Series uses 10 to 30μL of blood and provides results in 17 minutes. It also helps in improving the efficiency and standardising the testing.

Sysmex’s new test measures the ratio of Aβ peptides (the 1-42 peptide and 1-40 peptide) in the blood to determine the Aβ accumulation in the brain.

This facilitates the earlier diagnosis and optimal treatment for patients, which is essential for the treatment of Alzheimer’s disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sysmex is preparing to launch the minimally invasive and simple test in Japan market, as soon as possible.

It stated that the new HISCL β-Amyloid 1-42 Assay Kit and the HISCL β-Amyloid 1-40 Assay Kit enables testing with blood, unlike other traditional testing methods.

This reduces the physical, and financial burden on patients who are suspected of Aβ accumulation in the brain.

According to Sysmex, Alzheimer’s disease is the most common form of dementia and accounts for nearly 60% to 70% of all cases.

It is caused by accumulation of Aβ peptides in the brain. This causes damage to the nerve cells, which cannot be regenerated once damaged.

The company stated that the diagnosis of Alzheimer’s disease requires advanced technology to identify the accumulation of Aβ in the brain.